The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic...

Area of Science:

• Molecular biology
• Biochemistry
• Cancer research

Background:

• The RAF/MEK/ERK kinase cascade's regulation is not fully understood.
• RAF dimerization is a critical activation step.
• RAF isoforms (ARAF, BRAF, CRAF) play roles in cell signaling.

Purpose of the Study:

• Investigate how RAF mutations affect kinase activation and dimerization.
• Characterize the oncogenic potential and inhibitor resistance of novel RAF mutants.
• Elucidate the molecular basis for differential RAF isoform activity in the MEK-ERK pathway.

Main Methods:

• Generation and characterization of RAF mutants with in-frame deletions in the β3-αC loop.
• Assays to measure kinase activity, dimerization affinity, and oncogenic potential.
• In vitro studies to assess MEK phosphorylation by RAF mutants.

Main Results:

• In-frame deletions in the β3-αC loop enforce RAF homodimerization and activate ARAF, BRAF, and other kinases.
• ARAF exhibits lower allosteric and catalytic activity due to its APE motif.
• RAF mutants show significant oncogenic potential and differential inhibitor resistance linked to dimer affinity.
• Active RAFs, including BRAF(V600E), phosphorylate MEK in a dimer-dependent manner.

Conclusions:

• This study identifies a novel class of oncogenic kinase mutations driven by enforced dimerization.
• Reveals the molecular basis for RAF isoform-specific differences in MEK-ERK pathway activation.
• Highlights RAF dimer affinity as a determinant of inhibitor resistance and a potential therapeutic target.